Prostate Cancer Imaging With Radioactive Tracer and Ultrasound Detector Compared to MRI and ProstaScint

July 12, 2011 updated by: Radiological Associates of Sacramento Medical Group Inc.

Exploratory Evaluation of a Transrectal Scintigraphic Detector (Proxiscan) for Detection of Primary Prostate Cancer Utilizing a Radiotracer Targeting Prostate Specific Membrane Antigen (PMSA)

This is a small study to determine if probe, similar to an ultrasound probe, can detect prostate cancer more specifically than other imaging studies in patients with a positive prostate cancer biopsy.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

12

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Roseville, California, United States, 95661
        • Roseville PET and Nuclear Imaging Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Primary prostate cancer proven by sextant prostate biopsy
  • Transrectal ultrasound (TRUS)-guided prostate biopsy within 6 months of study enrollment
  • Sufficient time period to complete imaging protocol and 5-7 day safety followup assessment without other therapeutic intervention
  • In the judgement of principal investigator, patient able to provide informed consent and be compliant with protocol requirements
  • ECOG status of 0 or 1 Pt > 18 yrs of age

Exclusion Criteria:

  • Definitive or concomitant therapeutic intervention within the interval of study intervention
  • Prior pelvic therapeutic radiation
  • Active malignancy or therapy for malignancy with 6 months other than basal or squamous cell carcinoma of the skin
  • Pt received radiopharmaceutical which was within 5 half-lives at the time of studying imaging
  • Known history of human-anti-murine-antibodies or known allergic reaction to previously received murine based products

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: No intervention
All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
Device: Proxiscan device
All patients will be imaged with the device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Detection of PSMA antibody (ProstaScint)uptake patterns measured by Proxiscan in comparison with anatomic biopsy reports, conventional SPECT and MRI scans within one month of Proxiscan
Time Frame: Within on month of scan and corresponding MRI
Detection of PSMA antibody (ProstaScint) uptake patterns measured by the new transrectal compact gamma camera (Proxiscan) will be compared to the anatomic biopsy reports along with Magnetic Resonance Imaging (MRI) and conventional ProstaScint (Single Photon Emission Computed Tomography) SPECT imaging results. All imaging and biopsy results performed within one month will be used for this investigation
Within on month of scan and corresponding MRI

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Radiological Associates of Sacramento Medical Group Inc.

Collaborators

Hybridyne Imaging Technologies

Investigators

  • Principal Investigator: Benjamin Franc, MD, Radiological Associates of Sacramento Medical Group Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (Anticipated)

December 1, 2011

Study Completion (Anticipated)

March 1, 2012

Study Registration Dates

First Submitted

July 1, 2011

First Submitted That Met QC Criteria

July 12, 2011

First Posted (Estimate)

July 14, 2011

Study Record Updates

Last Update Posted (Estimate)

July 14, 2011

Last Update Submitted That Met QC Criteria

July 12, 2011

Last Verified

July 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Proxiscan

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on Proxiscan device

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe